MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

This is a single-center randomized trial that investigates microwave ablation (MWA) combined with EGFR-TKI therapy in 120 early-stage NSCLC patients (T1-T2N0M0, EGFR-mutant) unsuitable for standard treatments. Participants are stratified by tumor characteristics and randomized equally to MWA alone, MWA-TKI concurrent, or TKI induction followed by MWA-TKI, assessing disease-free survival, overall survival, and safety outcomes. The study compares the clinical benefits and optimal sequencing of local ablation with targeted therapy in early-stage EGFR-mutant NSCLC management.

NCT Number	NCT06969781
Lead Sponsor	Shanghai Chest Hospital Collaborators: Shanghai Allist Pharmaceuticals Co.,Ltd.
Conditions	Lung Cancer (NSCLC)
Enrollment	120 participants
Start Date	2025-05
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2025-05-14